Telehealth for IBD: What a Cochrane Review Found About Remote Care

For many people living with inflammatory bowel disease, accessing regular specialist care is one of the more demanding practical realities of managing the condition. Gastroenterology appointment slots fill up weeks in advance, flare symptoms do not always align neatly with scheduled visits, and for patients based far from specialist centres, geography adds a further layer of difficulty.

Digital tools, including smartphone apps, web-based monitoring platforms, and telephone-based care models, have been proposed as one way to change the shape of IBD care. But what does the evidence actually say about whether these tools work?

A 2023 Cochrane systematic review addressed this question directly. The review, authored by Gordon and colleagues and published in the Cochrane Database of Systematic Reviews, examined randomised controlled trials that tested remote care technologies against standard outpatient care for people with IBD (Gordon M, Sinopoulou V, Lakunina S, et al., Cochrane, 2023).

What the Review Examined

The review assessed a range of telehealth approaches used in IBD care, including:

• Web-based self-monitoring platforms where patients log symptoms, medication use, and wellbeing indicators, with clinicians reviewing data remotely
• Smartphone apps designed for IBD tracking, sometimes connected directly to care teams
• Telephone-based follow-up as a replacement for some routine face-to-face outpatient appointments
• Combined digital and remote monitoring tools that integrate patient-reported data with clinician oversight

The review assessed effects on disease activity, quality of life, hospital admissions, patient satisfaction, and healthcare resource use.

What the Evidence Found

The overall picture from the review is that remote care tools appear to produce broadly similar outcomes to standard outpatient care across several key measures, but the evidence base is limited in size and quality, which matters for how to interpret the results.

On disease activity, some trials found that web-based monitoring was associated with comparable disease control to standard outpatient appointments. Patients using remote tools did not appear to have worse disease outcomes than those receiving conventional care, though the certainty of evidence supporting this finding is low.

On quality of life, results were mixed across individual trials. Some remote care approaches were associated with maintained or slightly improved quality of life scores compared with standard care. Patient satisfaction with telehealth tools was generally high, with many participants reporting that remote access reduced the practical burden of travel and waiting time.

On hospital admissions and unplanned care use, the evidence did not show a consistent difference between telehealth and standard care groups, though some individual trials reported fewer unplanned admissions in groups using digital monitoring tools.

The review authors noted that the certainty of evidence across most outcomes is low to very low, reflecting the small number of available trials, the variation in the types of technology studied, and differences in how outcomes were measured across studies.

Why Evidence Certainty Matters Here

A Cochrane systematic review pools the best available randomised trial evidence on a question. A low certainty rating does not mean the finding is wrong; it means that further well-designed trials could change the picture. In a field like digital health, the technology landscape also evolves faster than clinical trial evidence can follow, which means what was tested in trials a few years ago may look different from tools available today.

For IBD patients, this means that telehealth tools are not yet supported by the same depth of evidence as established drug treatments or procedural care, but the available data do not point toward harm from using them, and patient experience with these tools has generally been positive across studies.

What This Means in Practice

The Cochrane review does not endorse any specific app or platform. Its contribution is a structured map of what the available trial evidence shows about remote care for IBD as a category.

The NHS notes that specialist IBD nurses can provide telephone or remote advice as part of a wider care team, and that regular outpatient review remains a core part of IBD management for most people (NHS: Inflammatory Bowel Disease). In clinical practice, telehealth tools are most commonly offered as a complement to, rather than a replacement for, specialist outpatient care.

For patients interested in remote monitoring, the starting point is a conversation with their gastroenterologist or IBD nurse, who can advise on what tools, if any, are available through their care team and how they might fit into their current care plan.